The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3

SUMMARY: Maturity-onset diabetes of the young type 3 (MODY3) accounts for approximately 50% of cases of MODY. First-line treatment with sulfonylureas has been well established for individuals with MODY3. In contrast, the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors in the treatment of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sriravindrarajah, Arunan, Fernandes, Amelia, Wu, Ted, Hocking, Samantha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2021
Materias:
Novel Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686174/
https://www.ncbi.nlm.nih.gov/pubmed/34866061
http://dx.doi.org/10.1530/EDM-21-0102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686174/
https://www.ncbi.nlm.nih.gov/pubmed/34866061
http://dx.doi.org/10.1530/EDM-21-0102

Ejemplares similares